Neuphoria Therapeutics (NEUP) Equity Ratio (2020 - 2025)
Historic Equity Ratio for Neuphoria Therapeutics (NEUP) over the last 6 years, with Q4 2025 value amounting to 0.81.
- Neuphoria Therapeutics' Equity Ratio rose 724.59% to 0.81 in Q4 2025 from the same period last year, while for Dec 2025 it was 0.81, marking a year-over-year increase of 724.59%. This contributed to the annual value of 0.66 for FY2025, which is N/A changed from last year.
- Per Neuphoria Therapeutics' latest filing, its Equity Ratio stood at 0.81 for Q4 2025, which was up 724.59% from 0.46 recorded in Q3 2025.
- Neuphoria Therapeutics' 5-year Equity Ratio high stood at 0.89 for Q4 2021, and its period low was 0.46 during Q3 2025.
- Over the past 5 years, Neuphoria Therapeutics' median Equity Ratio value was 0.77 (recorded in 2023), while the average stood at 0.76.
- Data for Neuphoria Therapeutics' Equity Ratio shows a peak YoY increase of 724.59% (in 2025) and a maximum YoY decrease of 3857.83% (in 2025) over the last 5 years.
- Quarter analysis of 5 years shows Neuphoria Therapeutics' Equity Ratio stood at 0.89 in 2021, then dropped by 1.93% to 0.87 in 2022, then dropped by 11.55% to 0.77 in 2023, then decreased by 1.83% to 0.76 in 2024, then rose by 7.25% to 0.81 in 2025.
- Its Equity Ratio was 0.81 in Q4 2025, compared to 0.46 in Q3 2025 and 0.66 in Q2 2025.